| Literature DB >> 15609239 |
John A Mikszta1, Vincent J Sullivan, Cheryl Dean, Andrea M Waterston, Jason B Alarcon, John P Dekker, John M Brittingham, Juan Huang, C Robin Hwang, Matthew Ferriter, Ge Jiang, Kevin Mar, Kamal U Saikh, Bradley G Stiles, Chad J Roy, Robert G Ulrich, Noel G Harvey.
Abstract
A new anthrax vaccine under clinical investigation is based on recombinant Bacillus anthracis protective antigen (rPA). Here, we investigated microneedle-based cutaneous and nasal mucosal delivery of rPA in mice and rabbits. In mice, intradermal (id) delivery achieved up to 90% seroconversion after a single dose, compared with 20% after intramuscular (im) injection. Intranasal (inl) delivery of a liquid formulation required 3 doses to achieve responses that were comparable with those achieved via the id or im routes. In rabbits, id delivery provided complete protection against aerosol challenge with anthrax spores; in addition, novel powder formulations administered inl provided complete protection, whereas a liquid formulation provided only partial protection. These results demonstrate, for the first time, that cutaneous or nasal mucosal administration of rPA provides complete protection against inhalational anthrax in rabbits. The novel vaccine/device combinations described here have the potential to improve the efficacy of rPA and other biodefense vaccines.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15609239 DOI： 10.1086/426865
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226